Sight Sciences Stock Today
| SGHT Stock | USD 3.91 0.07 1.76% |
Performance0 of 100
| Odds Of DistressOver 63
|
Sight Sciences is selling for under 3.91 as of the 28th of November 2024; that is 1.76 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.91. Sight Sciences has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Sight Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of July 2021 | Category Healthcare | Classification Health Care |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company was incorporated in 2010 and is headquartered in Menlo Park, California. The company has 50.4 M outstanding shares of which 1.12 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover. More on Sight Sciences
Moving together with Sight Stock
Moving against Sight Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Sight Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSight Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sight Sciences' financial leverage. It provides some insight into what part of Sight Sciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sight Sciences (SGHT) is traded on NASDAQ Exchange in USA. It is located in 4040 Campbell Avenue, Menlo Park, CA, United States, 94025 and employs 214 people. Sight Sciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 200.58 M. Sight Sciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 50.4 M outstanding shares of which 1.12 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover.
Sight Sciences currently holds about 220.1 M in cash with (47.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sight Sciences Probability Of Bankruptcy
Ownership AllocationSight Sciences shows a total of 50.4 Million outstanding shares. Over half of Sight Sciences' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sight Ownership Details
Sight Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 325.8 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 321.6 K | |
| Millennium Management Llc | 2024-06-30 | 296.3 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 257 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 207.9 K | |
| Panagora Asset Management Inc | 2024-09-30 | 194.8 K | |
| National Asset Management Inc | 2024-06-30 | 185.1 K | |
| Millrace Asset Group, Inc | 2024-09-30 | 138.8 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 136 K | |
| Bank Of America Corp | 2024-06-30 | 3.1 M | |
| Ubs Group Ag | 2024-06-30 | 2.9 M |
Sight Sciences Historical Income Statement
Sight Stock Against Markets
Sight Sciences Corporate Management
| MBA BS | VP Operations | Profile | |
| Stacie Rodgers | VP HR | Profile | |
| John Liu | VP Access | Profile | |
| Stephen JD | Secretary | Profile | |
| Reay MD | Chief Officer | Profile | |
| Sam Park | Chief Officer | Profile | |
| John Ordway | VP Operations | Profile |
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.